| Ytd | 160.69% | |
| 1y | 160.69% |
| Open | 100.00 | Prev Close | 97.93 | Low | 97.14 | High | 101.38 | Mkt Cap | 4.11B |
| Vol | 678.22K | Avg Vol | 722.12K | EPS | -2.50 | P/E | N/A | Forward P/E | -36.56 |
| Beta | N/A | Short Ratio | 4.76 | Inst. Own | 97.89% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 11-12 | 50-d Avg | 111.31 | 200-d Avg | 86.97 | 1yr Est | 163.50 |
MANE News
Bamco Inc. NY increased its position in shares of Veradermics, Incorporated (NYSE: MANE) by 284.8% d
Veradermics (NYSE:MANE) reported quarterly losses of $(0.58) per share which beat the analyst consen
Veradermics, Incorporated (NYSE:MANE), a dermatologist-founded, late-stage biopharmaceutical company
Citigroup analyst Geoff Meacham maintains Veradermics (NYSE:MANE) with a Buy and raises the price
Veradermics reported positive phase 2 data for VDPHL01, showing hair growth and favorable safety in
Needham analyst Serge Belanger maintains Veradermics (NYSE:MANE) with a Buy and raises the price
Gainers China Pharma Holding (AMEX:CPHI) shares moved upwards by 67.6% to $1.03 during Wednesday
US stocks close higher, Dow Jones up 100 points, PayPal shares rise on $53 billion acquisition propo
VDPHL01, a novel orally-administered extended-release minoxidil formulation, achieved fast onset of
B. Riley Securities analyst Mayank Mamtani initiates coverage on Veradermics (NYSE:MANE) with a B
Jefferies analyst Roger Song maintains Veradermics (NYSE:MANE) with a Buy and raises the price ta
LifeSci Capital analyst Rami Katkhuda initiates coverage on Veradermics (NYSE:MANE) with a Outper
Wall Street analysts changed outlook on top names: ODTX, MOBI, MANE. See analyst ratings page for al
Needham analyst Serge Belanger initiates coverage on Veradermics (NYSE:MANE) with a Buy rating an
Veradermics, Incorporated (NYSE:MANE), a dermatologist-founded, late clinical-stage biopharmaceutica
Veradermics, Incorporated (NYSE:MANE), a dermatologist-founded, late clinical-stage biopharmaceutica
U.S. stocks trade lower on Monday, with Dow falling 0.1%. Verizon beats Q1 earnings, raises FY26 gui
Veradermics reports Phase 2/3 data for VDPHL01, showing significant hair growth and a safety profile
U.S. stocks were lower, Dow Jones fell 0.1% on Monday. XOMA shares rose on Ligand's plans to acq
VDPHL01, a novel orally-administered extended-release minoxidil formulation, met all primary and all
Leerink Partners analyst Marc Goodman maintains Veradermics (NYSE:MANE) with a Outperform and rai